Yes, components of degradation pathways can serve as biomarkers for cancer diagnosis and prognosis. Elevated levels of certain degraded proteins or nucleic acids in the blood or tissues can indicate the presence of cancer or its aggressiveness. For instance, increased levels of circulating cell-free DNA (cfDNA) are often associated with tumor burden and can be used to monitor treatment response.